<DOC>
	<DOCNO>NCT00414609</DOCNO>
	<brief_summary>The core extension study assess safety efficacy aliskiren add optimized standard therapy patient high risk acute myocardial infarction ( heart attack ) .</brief_summary>
	<brief_title>Safety Efficacy Aliskiren Post Myocardial Infarction Patients ( ASPIRE )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Core Study Male female patient 18 year old . Patients within 742 day acute myocardial infarction associate leave ventricular systolic dysfunction . Documented leave ventricular systolic dysfunction associate qualify acute myocardial . Patients must stable dos follow concomitant medication least 2 week prior Visit 1 unless contraindicate due intolerance : A Betablocker An Antiplatelet agent A Statin An evidencebased dose Angiotensin Converting Enzyme Inhibitor ( ACEI ) Angiotensin Receptor Blocker ( ARB ) . Qualifying Echocardiogram Visit 1 : Core Study Patients require Angiotensin Converting Enzyme Inhibitor ( ACEI ) Angiotensin Receptor Blocker ( ARB ) combination therapy V1 time study . Severe refractory hypertension define mean sit systolic blood pressure ( MSSBP ) ≥ 180 mmHg and/or mean sit diastolic blood pressure ( MSDBP ) ≥ 110 mmHg ) Visit 2 . Cardiogenic shock systolic BP &lt; 100 mmHg diastolic &lt; 60 mmHg within 24 hour prior Visits 1 2 Estimated Glomerular Filtration Rate ( eGFR ) &lt; 30 ml/min/1.73m2 use MDRD formula Visit 1 . Stroke transient ischemic event ( TIA ) within 6 month Study Visit 1 Extension Study Male female patient complete core study Visit 10 doubleblind study drug Patients able participate study , consent purpose nature study clearly explain ( write inform consent ) Extension Study New York Heart Association ( NYHA ) class IV Congestive Heart Failure Visit 1 ( Core study Visit 10 ) Symptomatic hypotension report systolic blood pressure ( BP ) &lt; 90 mmHg within 24 hour prior Visit 1 ( Core study Visit 10 ) Known Estimated Glomerular Filtration Rate ( eGFR ) &lt; 30 mL/min/1.73m^2 use Modification Diet Renal Disease ( MDRD ) formula Visit 1 ( Core study Visit 10 ) Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) Women childbearing potential , defined woman physiologically capable become pregnant Unless postmenopausal use acceptable method contraception Any surgical medical condition opinion investigator may place patient high risk his/her participation study likely prevent patient comply requirement complete study Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>myocardial infarction , aliskiren , heart failure</keyword>
	<keyword>Post acute myocardial infarction systolic dysfunction</keyword>
</DOC>